Long-term follow-up of 246 hyperprolactinemic patients
Background. We wanted to evaluate the very long‐term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients. Methods. We conducted a retrospective cohort study in the Department of Endocrinology from Necker Hospital in Paris, Fran...
Gespeichert in:
| Veröffentlicht in: | Acta obstetricia et gynecologica Scandinavica 2001-02, Vol.80 (2), p.162-168 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 168 |
|---|---|
| container_issue | 2 |
| container_start_page | 162 |
| container_title | Acta obstetricia et gynecologica Scandinavica |
| container_volume | 80 |
| creator | Touraine, Philippe Plu-Bureau, Geneviève Beji, Claudine Mauvais-Jarvis, Pierre Kuttenn, Frédérique |
| description | Background. We wanted to evaluate the very long‐term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients.
Methods. We conducted a retrospective cohort study in the Department of Endocrinology from Necker Hospital in Paris, France. Two hundred and forty‐six patients consulted primarily for menstrual disorders, with diagnosis of hyperprolactinemia. Patients were followed‐up for 99.9±3.6 months. One hundred and ninety‐one were treated with bromocriptine, 32 underwent surgery, and 23 received no treatment.
Results. The mean initial plasma PRL level was 135.0±20.2 ng/ml. Presence of an adenoma was detected in 60% of our patients and comprised a microadenoma in 64% of cases. Compared to oligomenorrheic women, amenorrheic patients had significantly higher levels of PRL and larger pituitary tumor size. In the bromocriptine group, PRL levels decreased from 99.6±7.9 to 20.0±1.5 ng/ml (p=0.00001). The medical treatment was associated with disappearance of the adenoma in 45% of the women and with stabilization of pituitary tumor size in 40% of patients. Surgery led to disappearance of the adenoma in almost all cases, but failed to definitively cure hyperprolactinemia.
Conclusion. In this large‐scale retrospective study, the medical treatment of mild hyperprolactinemia was shown to be effective and sufficient after 9 years of follow‐up. |
| doi_str_mv | 10.1034/j.1600-0412.2001.080002162.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70596421</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70596421</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4993-a7c620eb757fa94ec3970de811e7838d7f4923db6715f479c7924902024439a63</originalsourceid><addsrcrecordid>eNqVkNtKAzEQhoMotlZfQRYU73adHDYH8EaKVrFYEMXLkKZZ3bonky22b-8uLfXaqzDJN_9MPoQuMSQYKLteJpgDxMAwSQgATkACAMGcJOsDNNw_HqJhd49jTpkaoJMQll1FBJPHaIAx5oJgOkR8Wlcfcet8GWV1UdQ_8aqJ6iwijEefm8b5xteFsW1euTK3UWPa3FVtOEVHmSmCO9udI_R2f_c6foins8nj-HYaW6YUjY2wnICbi1RkRjFnqRKwcBJjJySVC5ExRehizgVOMyaUFYowBQQIY1QZTkfoapvbrfG9cqHVZR6sKwpTuXoVtIBUcdb9ZIRutqD1dQjeZbrxeWn8RmPQvTe91L0a3avRvTe996bXXfv5bs5qXrrFX_NOVAdc7AATrCkybyqbhz0neSpFT4231E9euM2_VtC3s4nsiz4l3qbkoXXrfYrxX5oLKlL9_jzRD_JJSpVO9Av9BbAXldE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70596421</pqid></control><display><type>article</type><title>Long-term follow-up of 246 hyperprolactinemic patients</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Touraine, Philippe ; Plu-Bureau, Geneviève ; Beji, Claudine ; Mauvais-Jarvis, Pierre ; Kuttenn, Frédérique</creator><creatorcontrib>Touraine, Philippe ; Plu-Bureau, Geneviève ; Beji, Claudine ; Mauvais-Jarvis, Pierre ; Kuttenn, Frédérique</creatorcontrib><description>Background. We wanted to evaluate the very long‐term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients.
Methods. We conducted a retrospective cohort study in the Department of Endocrinology from Necker Hospital in Paris, France. Two hundred and forty‐six patients consulted primarily for menstrual disorders, with diagnosis of hyperprolactinemia. Patients were followed‐up for 99.9±3.6 months. One hundred and ninety‐one were treated with bromocriptine, 32 underwent surgery, and 23 received no treatment.
Results. The mean initial plasma PRL level was 135.0±20.2 ng/ml. Presence of an adenoma was detected in 60% of our patients and comprised a microadenoma in 64% of cases. Compared to oligomenorrheic women, amenorrheic patients had significantly higher levels of PRL and larger pituitary tumor size. In the bromocriptine group, PRL levels decreased from 99.6±7.9 to 20.0±1.5 ng/ml (p=0.00001). The medical treatment was associated with disappearance of the adenoma in 45% of the women and with stabilization of pituitary tumor size in 40% of patients. Surgery led to disappearance of the adenoma in almost all cases, but failed to definitively cure hyperprolactinemia.
Conclusion. In this large‐scale retrospective study, the medical treatment of mild hyperprolactinemia was shown to be effective and sufficient after 9 years of follow‐up.</description><identifier>ISSN: 0001-6349</identifier><identifier>EISSN: 1600-0412</identifier><identifier>DOI: 10.1034/j.1600-0412.2001.080002162.x</identifier><identifier>PMID: 11167213</identifier><identifier>CODEN: AOGSAE</identifier><language>eng</language><publisher>Copenhagen: Munksgaard International Publishers</publisher><subject>Adenoma - complications ; Adenoma - drug therapy ; Adenoma - surgery ; Adult ; Biological and medical sciences ; Bromocriptine - therapeutic use ; bromocriptine treatment ; Estradiol - blood ; Female ; Follow-Up Studies ; Hormone Antagonists - therapeutic use ; Hormones. Endocrine system ; Humans ; hyperprolactinemia ; Hyperprolactinemia - drug therapy ; Hyperprolactinemia - etiology ; Medical sciences ; Pharmacology. Drug treatments ; pituitary adenoma ; Pituitary Neoplasms - complications ; Pituitary Neoplasms - drug therapy ; Pituitary Neoplasms - surgery ; prolactin ; Prolactin - blood ; Retrospective Studies</subject><ispartof>Acta obstetricia et gynecologica Scandinavica, 2001-02, Vol.80 (2), p.162-168</ispartof><rights>2001 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4993-a7c620eb757fa94ec3970de811e7838d7f4923db6715f479c7924902024439a63</citedby><cites>FETCH-LOGICAL-c4993-a7c620eb757fa94ec3970de811e7838d7f4923db6715f479c7924902024439a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1034%2Fj.1600-0412.2001.080002162.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1034%2Fj.1600-0412.2001.080002162.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=865873$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11167213$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Touraine, Philippe</creatorcontrib><creatorcontrib>Plu-Bureau, Geneviève</creatorcontrib><creatorcontrib>Beji, Claudine</creatorcontrib><creatorcontrib>Mauvais-Jarvis, Pierre</creatorcontrib><creatorcontrib>Kuttenn, Frédérique</creatorcontrib><title>Long-term follow-up of 246 hyperprolactinemic patients</title><title>Acta obstetricia et gynecologica Scandinavica</title><addtitle>Acta Obstet Gynecol Scand</addtitle><description>Background. We wanted to evaluate the very long‐term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients.
Methods. We conducted a retrospective cohort study in the Department of Endocrinology from Necker Hospital in Paris, France. Two hundred and forty‐six patients consulted primarily for menstrual disorders, with diagnosis of hyperprolactinemia. Patients were followed‐up for 99.9±3.6 months. One hundred and ninety‐one were treated with bromocriptine, 32 underwent surgery, and 23 received no treatment.
Results. The mean initial plasma PRL level was 135.0±20.2 ng/ml. Presence of an adenoma was detected in 60% of our patients and comprised a microadenoma in 64% of cases. Compared to oligomenorrheic women, amenorrheic patients had significantly higher levels of PRL and larger pituitary tumor size. In the bromocriptine group, PRL levels decreased from 99.6±7.9 to 20.0±1.5 ng/ml (p=0.00001). The medical treatment was associated with disappearance of the adenoma in 45% of the women and with stabilization of pituitary tumor size in 40% of patients. Surgery led to disappearance of the adenoma in almost all cases, but failed to definitively cure hyperprolactinemia.
Conclusion. In this large‐scale retrospective study, the medical treatment of mild hyperprolactinemia was shown to be effective and sufficient after 9 years of follow‐up.</description><subject>Adenoma - complications</subject><subject>Adenoma - drug therapy</subject><subject>Adenoma - surgery</subject><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Bromocriptine - therapeutic use</subject><subject>bromocriptine treatment</subject><subject>Estradiol - blood</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Hormone Antagonists - therapeutic use</subject><subject>Hormones. Endocrine system</subject><subject>Humans</subject><subject>hyperprolactinemia</subject><subject>Hyperprolactinemia - drug therapy</subject><subject>Hyperprolactinemia - etiology</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>pituitary adenoma</subject><subject>Pituitary Neoplasms - complications</subject><subject>Pituitary Neoplasms - drug therapy</subject><subject>Pituitary Neoplasms - surgery</subject><subject>prolactin</subject><subject>Prolactin - blood</subject><subject>Retrospective Studies</subject><issn>0001-6349</issn><issn>1600-0412</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqVkNtKAzEQhoMotlZfQRYU73adHDYH8EaKVrFYEMXLkKZZ3bonky22b-8uLfXaqzDJN_9MPoQuMSQYKLteJpgDxMAwSQgATkACAMGcJOsDNNw_HqJhd49jTpkaoJMQll1FBJPHaIAx5oJgOkR8Wlcfcet8GWV1UdQ_8aqJ6iwijEefm8b5xteFsW1euTK3UWPa3FVtOEVHmSmCO9udI_R2f_c6foins8nj-HYaW6YUjY2wnICbi1RkRjFnqRKwcBJjJySVC5ExRehizgVOMyaUFYowBQQIY1QZTkfoapvbrfG9cqHVZR6sKwpTuXoVtIBUcdb9ZIRutqD1dQjeZbrxeWn8RmPQvTe91L0a3avRvTe996bXXfv5bs5qXrrFX_NOVAdc7AATrCkybyqbhz0neSpFT4231E9euM2_VtC3s4nsiz4l3qbkoXXrfYrxX5oLKlL9_jzRD_JJSpVO9Av9BbAXldE</recordid><startdate>200102</startdate><enddate>200102</enddate><creator>Touraine, Philippe</creator><creator>Plu-Bureau, Geneviève</creator><creator>Beji, Claudine</creator><creator>Mauvais-Jarvis, Pierre</creator><creator>Kuttenn, Frédérique</creator><general>Munksgaard International Publishers</general><general>Taylor & Francis</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200102</creationdate><title>Long-term follow-up of 246 hyperprolactinemic patients</title><author>Touraine, Philippe ; Plu-Bureau, Geneviève ; Beji, Claudine ; Mauvais-Jarvis, Pierre ; Kuttenn, Frédérique</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4993-a7c620eb757fa94ec3970de811e7838d7f4923db6715f479c7924902024439a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adenoma - complications</topic><topic>Adenoma - drug therapy</topic><topic>Adenoma - surgery</topic><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Bromocriptine - therapeutic use</topic><topic>bromocriptine treatment</topic><topic>Estradiol - blood</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Hormone Antagonists - therapeutic use</topic><topic>Hormones. Endocrine system</topic><topic>Humans</topic><topic>hyperprolactinemia</topic><topic>Hyperprolactinemia - drug therapy</topic><topic>Hyperprolactinemia - etiology</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>pituitary adenoma</topic><topic>Pituitary Neoplasms - complications</topic><topic>Pituitary Neoplasms - drug therapy</topic><topic>Pituitary Neoplasms - surgery</topic><topic>prolactin</topic><topic>Prolactin - blood</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Touraine, Philippe</creatorcontrib><creatorcontrib>Plu-Bureau, Geneviève</creatorcontrib><creatorcontrib>Beji, Claudine</creatorcontrib><creatorcontrib>Mauvais-Jarvis, Pierre</creatorcontrib><creatorcontrib>Kuttenn, Frédérique</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Touraine, Philippe</au><au>Plu-Bureau, Geneviève</au><au>Beji, Claudine</au><au>Mauvais-Jarvis, Pierre</au><au>Kuttenn, Frédérique</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-term follow-up of 246 hyperprolactinemic patients</atitle><jtitle>Acta obstetricia et gynecologica Scandinavica</jtitle><addtitle>Acta Obstet Gynecol Scand</addtitle><date>2001-02</date><risdate>2001</risdate><volume>80</volume><issue>2</issue><spage>162</spage><epage>168</epage><pages>162-168</pages><issn>0001-6349</issn><eissn>1600-0412</eissn><coden>AOGSAE</coden><abstract>Background. We wanted to evaluate the very long‐term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients.
Methods. We conducted a retrospective cohort study in the Department of Endocrinology from Necker Hospital in Paris, France. Two hundred and forty‐six patients consulted primarily for menstrual disorders, with diagnosis of hyperprolactinemia. Patients were followed‐up for 99.9±3.6 months. One hundred and ninety‐one were treated with bromocriptine, 32 underwent surgery, and 23 received no treatment.
Results. The mean initial plasma PRL level was 135.0±20.2 ng/ml. Presence of an adenoma was detected in 60% of our patients and comprised a microadenoma in 64% of cases. Compared to oligomenorrheic women, amenorrheic patients had significantly higher levels of PRL and larger pituitary tumor size. In the bromocriptine group, PRL levels decreased from 99.6±7.9 to 20.0±1.5 ng/ml (p=0.00001). The medical treatment was associated with disappearance of the adenoma in 45% of the women and with stabilization of pituitary tumor size in 40% of patients. Surgery led to disappearance of the adenoma in almost all cases, but failed to definitively cure hyperprolactinemia.
Conclusion. In this large‐scale retrospective study, the medical treatment of mild hyperprolactinemia was shown to be effective and sufficient after 9 years of follow‐up.</abstract><cop>Copenhagen</cop><pub>Munksgaard International Publishers</pub><pmid>11167213</pmid><doi>10.1034/j.1600-0412.2001.080002162.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6349 |
| ispartof | Acta obstetricia et gynecologica Scandinavica, 2001-02, Vol.80 (2), p.162-168 |
| issn | 0001-6349 1600-0412 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70596421 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenoma - complications Adenoma - drug therapy Adenoma - surgery Adult Biological and medical sciences Bromocriptine - therapeutic use bromocriptine treatment Estradiol - blood Female Follow-Up Studies Hormone Antagonists - therapeutic use Hormones. Endocrine system Humans hyperprolactinemia Hyperprolactinemia - drug therapy Hyperprolactinemia - etiology Medical sciences Pharmacology. Drug treatments pituitary adenoma Pituitary Neoplasms - complications Pituitary Neoplasms - drug therapy Pituitary Neoplasms - surgery prolactin Prolactin - blood Retrospective Studies |
| title | Long-term follow-up of 246 hyperprolactinemic patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T07%3A33%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-term%20follow-up%20of%20246%20hyperprolactinemic%20patients&rft.jtitle=Acta%20obstetricia%20et%20gynecologica%20Scandinavica&rft.au=Touraine,%20Philippe&rft.date=2001-02&rft.volume=80&rft.issue=2&rft.spage=162&rft.epage=168&rft.pages=162-168&rft.issn=0001-6349&rft.eissn=1600-0412&rft.coden=AOGSAE&rft_id=info:doi/10.1034/j.1600-0412.2001.080002162.x&rft_dat=%3Cproquest_cross%3E70596421%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70596421&rft_id=info:pmid/11167213&rfr_iscdi=true |